Neuphoria Therapeutics Inc. - Common Stock, $0.00001 par value per share (NEUP) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2024 to Q4 2025

Type / Class
Equity / Common Stock, $0.00001 par value per share
Symbol
NEUP on Nasdaq
Shares outstanding
5,420,049
Price per share
$4.07
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
1,465,999
Total reported value
$5,687,252
% of total 13F portfolios
0%
Share change
+1,300,486
Value change
+$4,900,064
Number of holders
21
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Neuphoria Therapeutics Inc. - Common Stock, $0.00001 par value per share (NEUP) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ARMISTICE CAPITAL, LLC 5% $5,365,401 1,033,796 Armistice Capital, LLC 31 Dec 2024
Lynx1 Capital Management LP 16% 0% $3,877,703 875,328 0% Lynx1 Capital Management LP 26 Dec 2025
Baselake Partners, LP 4.1% -59% $862,110 222,222 0% Baselake Partners, LP 31 Dec 2025
Shay Capital LLC 7.3% $2,035,520 171,629 Shay Capital LLC 24 Oct 2025
Coastlands Capital LP 5.1% $1,423,200 120,000 Coastlands Capital LP 05 Nov 2025
Apeiron Investment Group Ltd. 4.5% $376,887 72,618 Apeiron Investment Group Ltd. 24 Jan 2025

As of 31 Dec 2025, 21 institutional investors reported holding 1,465,999 shares of Neuphoria Therapeutics Inc. - Common Stock, $0.00001 par value per share (NEUP). This represents 27% of the company’s total 5,420,049 outstanding shares.

Top 23 Institutional Shareholders

The largest institutional shareholders of Neuphoria Therapeutics Inc. - Common Stock, $0.00001 par value per share (NEUP) together control 27% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Lynx1 Capital Management LP 16% 875,228 0.69% $3,395,885
Shay Capital LLC 3.1% 169,059 0.11% $655,949
AdvisorShares Investments LLC 2.5% 134,194 +129% 0.09% $520,673
DIADEMA PARTNERS LP 0.92% 50,000 +133% 0.12% $194,000
Ikarian Capital, LLC 0.88% 47,443 0.02% $184,079
ADAR1 Capital Management, LLC 0.55% 30,000 0.01% $116,400
FNY Investment Advisers, LLC 0.49% 26,500 0.03% $102,000
VANGUARD GROUP INC 0.39% 20,950 0% 0% $81,286
GEODE CAPITAL MANAGEMENT, LLC 0.32% 17,303 +33% 0% $67,135
JANE STREET GROUP, LLC 0.31% 16,597 +5.9% 0% $64,396
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.27% 14,750 0% $57,230
BOOTHBAY FUND MANAGEMENT, LLC 0.26% 14,000 0% $54,320
Persistent Asset Partners Ltd 0.25% 13,403 +173% 0.02% $52,004
XTX Topco Ltd 0.22% 12,008 0% $46,591
COMMONWEALTH EQUITY SERVICES, LLC 0.21% 11,207 0% $43,480
Merck & Co., Inc. 0.18% 10,027 0% 0.01% $38,905
UBS Group AG 0.03% 1,652 -24% 0% $6,409
Tower Research Capital LLC (TRC) 0.03% 1,400 +241% 0% $5,432
RHUMBLINE ADVISERS 0% 202 +512% 0% $783
MORGAN STANLEY 0% 58 +729% 0% $225
BANK OF AMERICA CORP /DE/ 0% 18 +5.9% 0% $70
FMR LLC 0% 0 -100% $0
MILLENNIUM MANAGEMENT LLC 0% 0 -100% $0

Institutional Holders of Neuphoria Therapeutics Inc. - Common Stock, $0.00001 par value per share (NEUP) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 1,465,999 $5,687,252 +$4,900,064 $3.88 21
2025 Q3 195,338 $2,303,036 +$535,083 $11.79 15
2025 Q2 177,963 $1,263,538 +$105,431 $7.10 9
2025 Q1 163,114 $935,356 +$529,238 $5.76 7
2024 Q4 79,719 $273,435 +$239,042 $3.43 7